---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-053387"
form_type: "8-K"
ticker: "AEON"
cik: "0001837607"
company_name: "AEON Biopharma, Inc."
filed_at: "2023-05-01T23:59:59+00:00"
generated_at: "2026-06-16T05:19:00.488991+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Priveterra amends AEON Biopharma merger: lower cash condition, extended termination, new sponsor vesting terms

## Summary
- Minimum cash condition reduced from $45M to $40M; expense cap increased to $10.3M.
- 70% of founder shares (4.83M) become contingent, vesting based on $5.00 avg price or forfeited.
- Termination date extended to July 21, 2023; board set at 5 directors (2 AEON, 1 SPAC, 2 independent).
- Promissory note of up to $1M issued to sponsor, non-interest bearing, payable at business combination.
- Outstanding AEON RSUs and options converted to combined company equity with adjustments.

## SEC filing metadata
- accession: 0001104659-23-053387
- form_type: 8-K
- ticker: AEON
- cik: 0001837607
- company_name: AEON Biopharma, Inc.
- filed_at: 2023-05-01T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1837607/000110465923053387/0001104659-23-053387-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1837607/000110465923053387/tm2314221d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-053387
- JSON: https://secwatch.observer/filing/0001104659-23-053387.json
- Plain text: https://secwatch.observer/filing/0001104659-23-053387.txt

## Key facts
- Material Agreements
  AEON Biopharma, Inc. amended Amendment No. 1 to Sponsor Support Agreement with Priveterra Sponsor, LLC valued at Amendment to Sponsor Support Agreement - 70% of Founder Shares unvested and subject to forfeiture pr (effective 2023-04-27).
  - Action: amendment
  - Counterparty: Priveterra Sponsor, LLC
  - Value: Amendment to Sponsor Support Agreement - 70% of Founder Shares unvested and subject to forfeiture pr
  - Effective: 2023-04-27
  source text: On April 27, 2023, Priveterra, the Sponsor, AEON and the other parties thereto entered into an Amendment No. 1 to the Sponsor Support Agreement (the " SSA Amendment ").
  evidence_url: https://www.sec.gov/Archives/edgar/data/1837607/000110465923053387/0001104659-23-053387-index.htm
- Material Agreements
  AEON Biopharma, Inc. amended Amendment No. 1 to Business Combination Agreement with AEON Biopharma, Inc. valued at Amendment to Business Combination Agreement - reduced minimum cash condition from $45M to $40M, incr (effective 2023-04-27).
  - Action: amendment
  - Agreement: merger
  - Counterparty: AEON Biopharma, Inc.
  - Value: Amendment to Business Combination Agreement - reduced minimum cash condition from $45M to $40M, incr
  - Effective: 2023-04-27
  source text: On April 27, 2023, Priveterra, AEON and Merger Sub entered into an Amendment No. 1 to the Business Combination Agreement (the " BCA Amendment ").
  evidence_url: https://www.sec.gov/Archives/edgar/data/1837607/000110465923053387/0001104659-23-053387-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.